Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Lidocaine for Postoperative Pulmonary Complications in Minimally Invasive Esophagectomy
NCT06138041Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Feb 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of Lidocaine Hydrochloride Injection, without epinephrine in postoperative pulmonary complications (PPC), postoperative pneumonia, pulmonary atelectasis (ATX) and 1 more (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Incidence of Postoperative Pulmonary Complications at 7 days. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
Lidocaine Hydrochloride Injection, without epinephrine
03
Conditions
postoperative pulmonary complications (PPC)postoperative pneumoniapulmonary atelectasis (ATX)pulmonary edema
Beyond the preview
Go deeper on NCT06138041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138041.